GlassScriptPhysician profile
Joshua M Evans
NPI 1376830539
$2,455.81
in general payments reported to CMS, 2019-2025
39 companies · $740 in 2025
The $740 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $292 · 2020: $142 · 2021: $304 · 2022: $402 · 2023: $329 · 2024: $248 · 2025: $740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,301 · Entertainment: $15.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,300.82 |
| Entertainment | $15.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gm Pharmaceuticals, INC. | $349.77 | 2025 | Vanacof |
| Corcept Therapeutics | $239.68 | 2025 | Korlym |
| Novo Nordisk INC | $235.11 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $235.01 | 2021-2024 | |
| Sunovion Pharmaceuticals INC. | $153.21 | 2019-2022 | |
| Glaxosmithkline, LLC. | $106.24 | 2021-2023 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $100.78 | 2022-2023 | |
| Dexcom, INC. | $93.84 | 2021-2023 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $78.37 | 2019-2023 | |
| Astellas Pharma US INC | $71.90 | 2019-2023 | Veozah |
| Astrazeneca Pharmaceuticals LP | $69.48 | 2022-2024 | Farxiga, Breztri |
| Sumitomo Pharma America, INC. | $68.18 | 2023-2024 | Gemtesa |
| Xeris Pharmaceuticals, INC. | $44.92 | 2020-2022 | |
| Mylan Specialty L.P. | $42.52 | 2021 | |
| Eisai INC. | $41.52 | 2020 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.